Kuang Shuman, Piao Mingjian, Li Chengjie, Zhang Nan, Li Jiongyuan, Li Shuofeng, Tian Binhe, Zhao Lijin, Zhao Haitao
Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan District, Zunyi, 563000, Guizhou, China.
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, 100730, Beijing, China.
Discov Oncol. 2025 Aug 22;16(1):1597. doi: 10.1007/s12672-025-03458-3.
Immunotherapy, remarkably immune checkpoint inhibitors, has shown significant efficacy and survival benefits in patients with various solid tumors. Although T lymphocytes have been extensively studied as the primary target cells, the role and application of B cells in solid tumor immunotherapy remain less understood.
In this study, we conducted a bibliometric analysis of articles on solid tumor immunotherapy related to B cells, published from 2003 to March 28, 2024, in the Web of Science Core Collection. Co-authorship and keyword co-occurrence analyses were performed using VOSviewer, while CiteSpace was used to identify burst keywords and references.
A total of 1995 publications were analyzed, revealing a year-on-year increase in articles. The most common keywords are "immunotherapy" and "expression". The most frequently referenced publications focused on tertiary lymphoid structures and B-cell markers. The United States and China are the largest contributors to this field, with Frontiers in Immunology being the most prolific journal. This study provides a comprehensive overview of over 20 years of B cell and immunotherapy research in solid tumors, identifying key countries, institutions, authors, journals, and publications.
The findings offer valuable insights into the relationship between B cells and immunotherapy in solid tumors. This study primarily unveils the current research hotspots concerning the role of B cells in immunotherapy, encompassing both fundamental research and clinical trials, as well as the accelerating emergence of an increasing number of B-cell-centric immunotherapies.
免疫疗法，尤其是免疫检查点抑制剂，已在多种实体瘤患者中显示出显著疗效和生存获益。尽管T淋巴细胞作为主要靶细胞已得到广泛研究，但B细胞在实体瘤免疫治疗中的作用和应用仍了解较少。
在本研究中，我们对2003年至2024年3月28日发表在科学网核心合集中的与B细胞相关的实体瘤免疫治疗文章进行了文献计量分析。使用VOSviewer进行共同作者和关键词共现分析，而CiteSpace用于识别突发关键词和参考文献。
共分析了1995篇出版物，显示文章数量逐年增加。最常见的关键词是“免疫疗法”和“表达”。被引用最频繁的出版物集中在三级淋巴结构和B细胞标志物。美国和中国是该领域的最大贡献者，《免疫学前沿》是发表文章最多的期刊。本研究全面概述了20多年来实体瘤中B细胞与免疫治疗的研究情况，确定了关键国家、机构、作者、期刊和出版物。
这些发现为实体瘤中B细胞与免疫治疗之间的关系提供了有价值的见解。本研究主要揭示了当前关于B细胞在免疫治疗中作用的研究热点，包括基础研究和临床试验，以及越来越多以B细胞为中心的免疫疗法的加速出现。
